ZK-283197

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Edgar181 (talk | contribs) at 19:08, 21 November 2018 (Filled in 1 bare reference(s) with reFill ()). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

ZK-283197
Clinical data
Other namesBAY 86-5310; SH-T04211C
Routes of
administration
By mouth[1]
Drug classEstrogen; Selective ERβ agonist
Identifiers
CAS Number

ZK-283197 (also known as BAY 86-5310 or SH-T04211C) is a selective and orally active ERβ agonist which was under development by Bayer Healthcare AG for the treatment of vasomotor symptoms.[1][2] It reached phase II clinical trials prior to the discontinuation of its development.[1] Its development was terminated in 2014.[1]

References

  1. ^ a b c d "ZK 283197 - AdisInsight". adisinsight.springer.com.
  2. ^ US 14/332,204, Pietras, R. J., & Jung, M. E., "Methods of using estrogen receptor-beta ligands as radiation mitigators"